Abstract Human herpesvirus (HHV)-6 reactivation is associated with severe forms of encephalitis among patients undergoing hematopoietic stem cell transplantation. Cases in non-neutropenic patients are uncommon. The efficacy of ganciclovir and other compounds that are used for the treatment of HHV-6 encephalitis remains suboptimal and linked to toxicity. Valganciclovir, the oral prodrug of ganciclovir, could be practical to treat outpatients, but it is not commonly used for severe cases. We report a case of HHV-6 encephalitis in a nonneutropenic patient successfully treated with valganciclovir and undergoing therapeutic drug monitoring in plasma and in the cerebrospinal fluid. Resolution of infectious foci was documented by cerebral MRI and F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). A review of the literature on HHV-6 encephalitis is also reported.
Introduction
Human herpesvirus (HHV)-6 is a universally acquired β-herpesvirus (Cone et al. 1993) . Similarly to other herpesviruses, HHV-6 can establish latency and subsequently reactivate, causing subclinical replication or clinical disease, especially in patients with immune deficits (Caserta et al. 2001; De Bolle et al. 2005) . Central nervous system (CNS) involvement has been mainly described in patients undergoing hematopoietic stem cell transplantation (HSCT) (Zerr 2006) . In these patients, HHV-6 typically presents as acute limbic encephalitis characterized by short-term memory loss, confusion, and disorientation (Seeley et al. 2007 ). Two distinct HHV-6 variants, HHV-6A and HHV6-B, have been reported (Boutolleau et al. 2006) . Although HHV-6 encephalitis is primarily caused by HHV-6 virus variant B, the reactivation of variant A can also be observed in CNS infections and in various neurological diseases (Razonable et al. 2002) .
Mortality and occurrence of cognitive sequelae among HSCT recipients with HHV-6 encephalitis remain high (30-50%) despite antiviral treatment with ganciclovir and/or foscarnet (Ogata et al. 2013) . Cerebrospinal fluid (CSF) penetration, although variable, has been demonstrated for antiviral drugs that are commonly used in cytomegalovirus (CMV) encephalitis; nevertheless, their efficacy in treating HHV-6
Electronic supplementary material The online version of this article (doi:10.1007/s13365-017-0566-4) contains supplementary material, which is available to authorized users. appear suboptimal (Ogata et al. 2013; Nau et al. 2010) . Valganciclovir, the oral prodrug of ganciclovir, has proved to be effective in the prophylaxis and treatment of CMV disease, but its use in severe forms is limited to a few cases (Biron 2006; Ljungman et al. 2011) . Therapeutic drug monitoring (TDM) is employed to monitor the efficacy and toxicity of ganciclovir (Ljungman et al. 2011) , although detection of CSF levels is usually not performed. Treatment duration is not well established and is usually based on clinical improvement and radiological responses using cerebral computed tomography (CT) and magnetic resonance imaging (MRI). The use of F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is not well established in HHV-6 disease monitoring but represents a promising tool (Wainwright et al. 2001) .
We report a case of HHV-6 encephalitis in a nonneutropenic patient successfully treated with valganciclovir and undergoing TDM in plasma and in the CSF. FDG-PET/ CT and cerebral MRI were used to document treatment response.
Case description
A 60-year-old man presented with a 1-week history of rapidly progressive disorientation, confabulation, short-term memory loss, and hypersomnia. Five months prior to the onset of symptoms, the patient was diagnosed with mixed cellularity Hodgkin lymphoma (HL, Ann Arbor stage IIIS B) and started chemotherapy with adriamycin, vinblastine, dacarbazine, and prednisone. Four weeks before the onset of neurological symptoms, a whole-body FDG-PET/CT documented significant disease improvement after 2 cycles of chemotherapy and no signs of cerebral lesions. At presentation, white blood cell differential count was within normal range. A brain magnetic resonance imaging (MRI) revealed the presence of limbic encephalitis (Fig. 1a) . FDG-PET/CT confirmed the absence of lymphoma progression but showed bilateral temporal mesial FDG-avid lesions consistent with infectious foci (Fig. 1c) . Scans were performed using a hybrid PET/CT scanner (Biograph 2; Siemens, Erlangen, Germany) as previously described (Bassetti et al. 2017) . Cerebrospinal fluid (CSF) analysis revealed mild elevations in protein concentration (519 mg/L) and WBC count (12 cells/μL, 90% lymphocytes) with normal glycorrhachia. CSF resulted positive for HHV-6 (6400 cp/mL) using real-time polymerase chain reaction (PCR) targeting the U67 open reading frame of HHV-6 as described elsewhere (Locatelli et al. 2000) . Other cultures and onconeuronal antigens were negative (Supplementary Material 1). Serum or intrathecal detection of HHV6-specific IgG antibody was not performed. Due to the patient's stable conditions and renal function (creatininemia 0.82 mg/dL, CrCl 110 mL/min), oral treatment with valganciclovir 900 mg every 12 h was started. Valganciclovir concentrations were measured according to a previously published HPLC-UV method (Zhao et al. 2012) and resulted within the range in ) were within the range at days 7, 14, 21, and 28 of treatment (1.33/9.93 mg/L, 0.76/7.58 mg/L, 0.75/5.34, 1.10/8.32, respectively) and did not require dose adjustments (laboratory targets 0.06-2.5 mg/L for trough level and < 15 mg/L for peak level). CSF concentrations performed at day 21 of treatment (arrow, filled circle) corresponded to 76% of plasma levels both plasma and CSF; valganciclovir CSF concentrations corresponded to 76% of plasma levels (Fig. 2) .
Clinical improvement of confusion and hypersomnolence was noted starting from 3 weeks of antiviral therapy. CSF examination showed normalization of protein concentration and WBC count along with a reduction of HHV-6 viral load to 1080 cp/mL. An MRI performed after 4 weeks of therapy showed a significant reduction of all cerebral lesions (Fig. 1b) . At the 8-week follow-up, clinical resolution of symptoms was reported and antiviral treatment discontinued.
An MRI performed 2 months after therapy discontinuation showed resolution of cerebral lesions (not shown). FDG-PET/ CT obtained 4 months after therapy discontinuation showed a complete resolution of the cerebral infectious foci without any detectable residual abnormal FDG-uptake (Fig. 1d) . At 1-year follow-up, the patient was asymptomatic without any evidence of CNS infection or HL relapse.
Discussion
HHV-6 reactivation is common among HSCT recipients, and CNS involvement has been shown in up to 11% of patients, especially following cord blood transplantation (Caserta et al. 2001 ). HHV-6 encephalitis has also been documented, although less frequently, among non-neutropenic patients including HIV-infected individuals, solid organ transplant (SOT) recipients, and people with lymphoproliferative disorders (Caserta et al. 2001) . Only a few cases of HHV-6 encephalitis have been reported in immunocompetent adults (Trabue et al. 2008) . We searched the Pubmed database for articles reporting cases of HHV-6 encephalitis in adult patients between 1996 and 2016. A total of 45 articles were retrieved (Supplementary Material 2). Of these, 22 (49%) included HSCT patients, 10 immunocompetent hosts, 5 SOT recipients, 3 patients receiving immunosuppressants, 3 HIV-positive patients, and 2 solid cancer patients. In our case, although WBC count was normal at presentation, risk factors for HHV-6 reactivation included HL diagnosis and recent chemotherapy. Thus, our case represents one of the cases of HHV-6 encephalopathy reported in hematological patients without neutropenia. The association between HHV-6 reactivation and HL, however, has been previously documented and should be taken into consideration when managing these patients. In HL, high HHV-6 viral load has been detected in samples of saliva and in up to 35% of lymph node biopsies (Collot et al. 2002) .
Diagnosis of HHV-6 encephalitis is mainly determined by HHV-6 DNA positivity in CSF (Caserta et al. 2001 ). HHV-6 real-time PCR, in particular, represents a reliable assay (Flamand et al. 2008) to differentiate between latent and active infection in immunocompromised patients due to the lack of reliable serological test for this patient population.
It has been argued, however, that CSF positivity may indicate a latent status due to HHV-6 neurotropism (Braun et al. 1997) . In particular, HHV-6 presence from brain tissue was demonstrated in one third of specimens taken from people without any signs of the disease (Cuomo et al. 2001) . In certain instances, detection of HHV-6 non-integration into the host genome could be useful to support the diagnosis of active disease. The diagnosis of HHV-6 encephalitis in our case was supported by suggestive clinical and radiological manifestations in the absence of other causative agents and in the presence of clinical response to antiviral treatment (Tavakoli et al. 2007 ). Imaging of FDG-PET/CT, in particular, documented a complete resolution of the infectious process and confirmed the absence of HL recurrence. While presence of increased glucose uptake on FDG-PET/CT has been previously documented in HHV-6 limbic encephalitis (Wainwright et al. 2001) , its role in documenting treatment response has not yet been investigated. Our report suggests that serial FDG-PET/TC may be used to monitor the evolution of HHV-6 encephalitis in hematological patients and could be a useful tool to consider in directing treatment duration along with clinical improvement and MRI changes.
Although ganciclovir, foscarnet, and cidofovir have shown in vitro activity against HHV-6, there is little clinical data to guide recommendations in clinical practice (Zerr 2006) . Valganciclovir is rapidly converted to ganciclovir after oral administration, and may represent a useful option for oral treatment. In our report, valganciclovir was successfully employed to treat HHV-6 encephalitis showing clinical, radiological, and virological responses. Among the cases retrieved from the literature, only two reported the use of valganciclovir for HHV-6 encephalitis. In one case, valganciclovir use for 6 weeks in an immunocompetent patient was followed by clinical improvement but persistence of long-term neurological deficits. In the other case, valganciclovir was used as a maintenance therapy following cidofovir in a patient undergoing HSCT (Isaacson et al. 2005; Bommer et al. 2009 ).
We did not differentiate between HHV-6 variant A or B. Detection of the HHV-6 strain could be useful since various 50% IC have been reported for antivirals, including ganciclovir. In particular, 50% IC for HHV-6B appeared higher in some reports (from 1.33 to 1.6 mg/L) compared to HHV-6A (0.65 mg/L) (Yoshida et al. 1998; Manichanh et al. 2000) . In our case, clinical resolution of symptoms was achieved with valganciclovir levels between 0.75 and 1.33 mg/L.
We performed valganciclovir TDM to confirm the presence of adequate plasma and CSF levels. Our reasons to perform TDM included the availability of the test at our facility and the fact that we could not exclude an impaired oral absorption leading to antiviral treatment underexposure. Although ganciclovir TDM is often used in the management of CMV infections, its association with HHV-6 therapy has rarely been reported, except for pediatric recipients known to have difficult-to-predict plasma concentrations (Janoly-Duménil et al. 2006; Vethamuthu et al. 2007) . It is known, however, that CSF concentrations of ganciclovir can vary significantly, ranging from 24 to 70% of plasma levels (Nau et al. 2010) . Furthermore, inadequate valganciclovir concentrations during prophylactic regimens have been previously reported (Vezina et al. 2014) . In hematological patients, clinical conditions that can influence drug concentrations (e.g., renal and/or hepatic impairment, mucositis, concomitant medications) are frequent. Thus, TDM could be helpful to detect ganciclovir under-or over-exposure that can potentially lead to treatment failure or toxicity.
In conclusion, HHV-6 represents a potential cause of meningoencephalitis in patients with lymphoproliferative diseases and should be considered in those presenting with suggestive clinical and radiological manifestations. Valganciclovir therapy can be effective in the treatment of severe HHV-6 forms. Although in our case dose adjustments were not necessary and we could not document their clinical effects following valganciclovir TDM, our data showed effective drug concentrations in both plasma and CSF. Given the lack of new compounds or guidelines to direct clinicians in the management of HHV-6 encephalitis, a careful use of the currently available antivirals is necessary. In this context, TDM can serve as a helpful tool to monitor drug concentrations, especially if variable drug levels are expected. Furthermore, use of serial FDG-PET/TC represents a useful tool to monitor treatment response and direct antiviral therapy duration.
